Unraveling Vulnerabilities in Endocrine Therapy-Resistant HER2+/ER+ Breast Cancer

BACKGROUND: Breast tumors overexpressing human epidermal growth factor receptor (HER2) confer intrinsic resistance to endocrine therapy (ET), and patients with HER2/ estrogen receptor-positive (HER2+/HR+) breast cancer (BCa) are less responsive to ET than HER2−/ER+. However, real-world evidence reve...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahnassy, Shaymaa, Stires, Hillary, Jin, Lu, Tam, Stanley, Mobin, Dua, Balachandran, Manasi, Podar, Mircea, McCoy, Matthew D., Beckman, Robert A., Riggins, Rebecca B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473676/
https://www.ncbi.nlm.nih.gov/pubmed/37662291
http://dx.doi.org/10.1101/2023.08.21.554116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473676/
https://www.ncbi.nlm.nih.gov/pubmed/37662291
http://dx.doi.org/10.1101/2023.08.21.554116

Ejemplares similares